Corbus Pharmaceuticals (NASDAQ:CRBP – Get Rating) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01, MarketWatch Earnings reports. Corbus Pharmaceuticals had a negative return on equity of 57.92% and a negative net margin of 2,856.56%.
Shares of CRBP traded down $0.01 during mid-day trading on Wednesday, reaching $0.25. 3,241 shares of the company’s stock traded hands, compared to its average volume of 1,094,259. The business’s 50-day moving average price is $0.40 and its 200-day moving average price is $0.57. The stock has a market capitalization of $31.32 million, a P/E ratio of -0.68 and a beta of 2.03. The company has a debt-to-equity ratio of 0.23, a quick ratio of 5.89 and a current ratio of 5.89. Corbus Pharmaceuticals has a 12 month low of $0.25 and a 12 month high of $2.29.
CRBP has been the topic of several research reports. Zacks Investment Research lowered Corbus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday. StockNews.com assumed coverage on Corbus Pharmaceuticals in a research note on Sunday. They set a “hold” rating for the company. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $1.83.
About Corbus Pharmaceuticals (Get Rating)
Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases.
- Get a free copy of the StockNews.com research report on Corbus Pharmaceuticals (CRBP)
- Wendy’s Growth Story Has Come To An End
- Beyond Meat Could Sizzle After Q1 Results Are Released
- Can Six Flags(SIX) or Cedar Fair (FUN) Give Investors a Thrill Later This Year?
- Inflation Hasn’t Peaked At Reynolds Consumer Products
- Is Now The Time To Buy Coinbase (NASDAQ: COIN)?
Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.